The World In A Grain Of Sand

By KdT Ventures

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the life science realm.... more

1919 ratings

FAQs about The World In A Grain Of Sand:

How many episodes does The World In A Grain Of Sand have?

The podcast currently has 14 episodes available.

The World In A Grain Of Sand episodes:

December 12, 2024The World in a Grain of Sand: BioAge
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was recorded before the clinical readout of BioAge's apelin receptor agonist Azelaprag.
We dive into:
BioAge's founding by first-time biotech entrepreneur Kristen Fortnoy as a Stanford spinout analyzing aging-related biomarkers

Their pivot from platform to asset in-licensing, securing Azelaprog from Amgen after discovering its potential in obesity when combined with GLP-1 drugs

Their clinical strategy running combination trials with both Lilly's Zepbound and Novo's Wegovy, supported by a strategic supply agreement giving Lilly first negotiation rights

A dramatic survival story of navigating near-death in 2022-2023 through bridge financing
...more
34min
May 29, 2024The World in a Grain of Sand: CG Oncology
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss CG Oncology, the first biotech IPO of 2024. We dive into:
The various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease

Supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer

CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer

Challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s lead asset

Bull vs bear case for CG Oncology
For updates from KdT, ⁠⁠subscribe to our Substack⁠⁠.
...more
44min
February 22, 2024The World in a Grain of Sand: Verve Therapeutics
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Ketan Yerneni and Mack Healy discuss Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. We dive into:
Base editing, and its advantages over traditional (potentially error-prone) CRISPR.

Verve’s pipeline, including their strategy of starting with genetically well-defined diseases like familial hypercholesterolemia and then expanding to the general population of patients with atherosclerotic cardiovascular disease.

Verve’s approach for predicting off-target gene editing, a key challenge for the gene editing field.

Verve’s unique licensing strategy with Beam, Acuitas, and the Broad to secure several foundational technologies.

The competitive landscape and target product profile tradeoffs for one-and-done gene editing approaches vs other therapeutic modalities.

and more.
For updates from KdT, ⁠subscribe to our Substack⁠.
...more
42min
September 05, 2023The World in a Grain of Sand: Schrödinger
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Patrick Malone and Mack Healy discuss the biopharma software juggernaut, Schrödinger. We dive into:
Schrödinger's biophysics-based drug discovery platform, and the distinction from machine learning approaches

A dissection of Schrödinger's software business, as well as co-development partnerships and internal therapeutic programs

The story of Schrödinger collaboration with Nimbus on a TYK2 program, resulting in a $4B+ acquisition by Takeda

and more
For updates from KdT, please subscribe to our Substack.
Show Notes:
Takeda Acquires Nimbus’ Tyk2 Autoimmune Program

Discovering Nimbus

Selective TYK2 Inhibition: A Story of Vision and Perseverance
...more
43min
April 19, 2023The World in a Grain of Sand: Amylyx Pharmaceuticals
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab

Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor

Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy

and more
For updates from KdT, please subscribe to our Substack.
...more
35min
March 08, 2023 The World in a Grain of Sand: Codiak BioSciences
KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Codiak BioSciences.
...more
38min
January 24, 2023 The World in a Grain of Sand: Royalty Pharma
KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Royalty Pharma.
...more
40min
October 07, 2022 The World in a Grain of Sand: Sana Biotechnology
KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Sana Biotechnology.
...more
38min
June 30, 2022 The World in a Grain of Sand: Editas
KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Editas.
...more
40min
May 17, 2022 The World in a Grain of Sand: Century Therapeutics
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Century Therapeutics.
...more
42min

FAQs about The World In A Grain Of Sand:

How many episodes does The World In A Grain Of Sand have?

The podcast currently has 14 episodes available.

More shows like The World In A Grain Of Sand

The Bill Simmons Podcast

30,112 Listeners

The Long Run with Luke Timmerman

116 Listeners

Business Of Biotech

82 Listeners

Share The World In A Grain Of Sand

Sign up to save your podcasts

The World In A Grain Of Sand

FAQs about The World In A Grain Of Sand:

How many episodes does The World In A Grain Of Sand have?

The World In A Grain Of Sand episodes:

FAQs about The World In A Grain Of Sand:

How many episodes does The World In A Grain Of Sand have?

More shows like The World In A Grain Of Sand

The Bill Simmons Podcast

The Long Run with Luke Timmerman

Business Of Biotech